alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › disproportionality

disproportionality

2 studies tagged disproportionality, dated 2026-06-22 to 2026-09-24. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Disproportionality analysis of adverse event signals associated with seven Alzheimer's drugs: insights from the FAERS database 2026-09-24
  2. Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system 2026-06-22

Studies

2 studies carry this tag.

Date range

2026

Top journals

  • Frontiers in pharmacology 2

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Disproportionality analysis of adverse event signals associated with seven Alzheimer's drugs: insights from the FAERS database

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Frontiers in pharmacology 2026-09-24 Treatments

    This study utilized FAERS data to compare adverse event reporting signals for seven anti-AD drugs.

  2. Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Frontiers in pharmacology 2026-06-22 Treatments

    Although both agents have demonstrated therapeutic potential, their post-marketing adverse event reporting profiles remain insufficiently characterized and compared in spontaneous reporting systems.

All topic tags with their study counts